ImmVirX receives $5.1 million R&D Tax Incentive
Melbourne, Australia 15 January 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $5,079,136 Research and Development (R&D) tax refund as part of the Australian Federal Government’s R&D […]
